{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T13:30:52Z","timestamp":1748007052905,"version":"3.37.3"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s10067-024-07248-0","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T07:45:15Z","timestamp":1733471115000},"page":"105-113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rates of glucocorticoid taper in the management of polymyalgia rheumatica: the science behind the \u201cart\u201d"],"prefix":"10.1007","volume":"44","author":[{"given":"Jenny","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Dafoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2753-2790","authenticated-orcid":false,"given":"Elaine","family":"Yacyshyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"5","key":"7248_CR1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/joim.13525","volume":"292","author":"IE Lundberg","year":"2022","unstructured":"Lundberg IE, Sharma A, Turesson C, Mohammad AJ (2022) An update on polymyalgia rheumatica. J Intern Med 292(5):717\u2013732","journal-title":"J Intern Med"},{"issue":"3","key":"7248_CR2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/art.30155","volume":"63","author":"CS Crowson","year":"2011","unstructured":"Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington K et al (2011) The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 63(3):633\u2013639","journal-title":"Arthritis Rheum"},{"issue":"5","key":"7248_CR3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.pec.2014.12.013","volume":"98","author":"H Twohig","year":"2015","unstructured":"Twohig H, Mitchell C, Mallen C, Adebajo A, Mathers N (2015) \u201cI suddenly felt I\u2019d aged\u201d: a qualitative study of patient experiences of polymyalgia rheumatica (PMR). Patient Educ Couns 98(5):645\u2013650","journal-title":"Patient Educ Couns"},{"key":"7248_CR4","doi-asserted-by":"publisher","unstructured":"Dasgupta B, M.-Kremers H, Mattesson EL (2010) Disease burden, quality of life and other measures in polymyalgia rheumatica. In: Preedy VR, Watson RR (eds) Handbook of disease burdens and quality of life measures [Internet]. New York, NY: Springer [cited 2024 Mar 17]. p. 3995\u20134012. Available from: https:\/\/doi.org\/10.1007\/978-0-387-78665-0_233","DOI":"10.1007\/978-0-387-78665-0_233"},{"issue":"2","key":"7248_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/RHU.0000000000000917","volume":"26","author":"AM Campbell","year":"2020","unstructured":"Campbell AM, Martin JR, Erstad BL (2020) Corticosteroid Tapering regimens in rheumatic disease: a systematic review. JCR J Clin Rheumatol 26(2):41\u201347","journal-title":"JCR J Clin Rheumatol"},{"issue":"1","key":"7248_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard-2022-223429","volume":"83","author":"C Dejaco","year":"2023","unstructured":"Dejaco C, Kerschbaumer A, Aletaha D, Bond M, Hysa E, Camellino D et al (2023) Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis 83(1):48\u201357","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"7248_CR7","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1001\/archinternmed.2009.352","volume":"169","author":"J Hernandez-Rodriguez","year":"2009","unstructured":"Hernandez-Rodriguez J, Cid MC, Lopez-Soto A, Espigol-Frigole G, Bosche X (2009) Treatment of polymyalgia rheumatica. Arch Intern Med 169(20):1839\u20131850","journal-title":"Arch Intern Med"},{"issue":"1","key":"7248_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.rdc.2015.08.009","volume":"42","author":"EL Matteson","year":"2016","unstructured":"Matteson EL, Buttgereit F, Dejaco C, Dasgupta B (2016) Glucocorticoids for management of polymyalgia rheumatica and giant cell arteritis. Rheum Dis Clin N Am 42(1):75\u201390","journal-title":"Rheum Dis Clin N Am"},{"issue":"10","key":"7248_CR9","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.39333","volume":"67","author":"C Dejaco","year":"2015","unstructured":"Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S et al (2015) 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology Collaborative Initiative. Arthritis Rheumatol 67(10):2569\u20132580","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"7248_CR10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/rheumatology\/kep303a","volume":"49","author":"B Dasgupta","year":"2010","unstructured":"Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J et al (2010) BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology 49(1):186\u2013190","journal-title":"Rheumatology"},{"key":"7248_CR11","doi-asserted-by":"crossref","unstructured":"Weyand CM, Goronzy JJ (2014) Giant-cell arteritis and polymyalgia rheumatica. In: Solomon CG (ed) N Engl J Med 371(1):50\u20137","DOI":"10.1056\/NEJMcp1214825"},{"key":"7248_CR12","unstructured":"British Society for Rheumatology [Internet]. Guideline revision: Polymyalgia rheumatica scope. Available from: https:\/\/www.rheumatology.org.uk\/news\/details\/Guideline-revision-Polymyalgia-rheumatica-scope. Accessed 27\u00a0Jul 2024"},{"issue":"1","key":"7248_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10067-021-05819-z","volume":"41","author":"A Floris","year":"2022","unstructured":"Floris A, Piga M, Chessa E, Congia M, Erre GL, Angioni MM et al (2022) Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. Clin Rheumatol 41(1):19\u201331","journal-title":"Clin Rheumatol"},{"issue":"Suppl. 20","key":"7248_CR14","first-page":"S56","volume":"18","author":"C Li","year":"2000","unstructured":"Li C, Dasgupta B (2000) Corticosteroids in polymyalgia rheumatica - a review of different treatment schedules. Clin Exp Rheumatol 18(Suppl. 20):S56\u2013S57","journal-title":"Clin Exp Rheumatol"},{"key":"7248_CR15","first-page":"65","volume":"32","author":"HM Kremers","year":"2005","unstructured":"Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE (2005) Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 32:65\u201373","journal-title":"J Rheumatol"},{"issue":"8","key":"7248_CR16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1136\/ard.48.8.658","volume":"48","author":"V Kyle","year":"1989","unstructured":"Kyle V, Hazleman BL (1989) Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis. 48(8):658\u201361","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"7248_CR17","first-page":"1326","volume":"26","author":"MA Gonzalez-Gay","year":"1999","unstructured":"Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M, Dababneh A, Hajeer A, Ollier WE (1999) The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 26(6):1326\u20131332","journal-title":"J Rheumatol"},{"issue":"9","key":"7248_CR18","first-page":"1945","volume":"26","author":"J Narvaez","year":"1999","unstructured":"Narvaez J, Nolla-Sole JM, Clavaguera MT, Valverde-Garcia J, Roig-Escofet D (1999) Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis. J Rheumatol 26(9):1945\u20131952","journal-title":"J Rheumatol"},{"key":"7248_CR19","doi-asserted-by":"publisher","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","volume":"141","author":"R Caporali","year":"2004","unstructured":"Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C et al (2004) Prednisone plus methotrexate for polymyalgia rheumatica. Ann Intern Med 141:493\u2013500","journal-title":"Ann Intern Med"},{"issue":"4","key":"7248_CR20","first-page":"624","volume":"23","author":"G Ferraccioli","year":"1994","unstructured":"Ferraccioli G, Salaffi F, De Vita S, Casatta L, Bartoli E (1994) Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 23(4):624\u2013628","journal-title":"J Rheumatol"},{"issue":"9","key":"7248_CR21","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/imj.14779","volume":"50","author":"C Ruediger","year":"2020","unstructured":"Ruediger C, Nguyen L, Black R, Proudman S, Hill C (2020) Efficacy of methotrexate in polymyalgia rheumatica in routine rheumatology clinical care. Intern Med J 50(9):1067\u20131072","journal-title":"Intern Med J"},{"issue":"3","key":"7248_CR22","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00296-020-04783-2","volume":"41","author":"D Marsman","year":"2021","unstructured":"Marsman D, Bolhuis T, Broeder ND, Van Den Hoogen F, Den Broeder A, Van Der Maas A (2021) Effect of add-on methotrexate in polymyalgia rheumatica patients flaring on glucocorticoids tapering: a retrospective study. Rheumatol Int 41(3):611\u2013616","journal-title":"Rheumatol Int"},{"issue":"9","key":"7248_CR23","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1111\/ggi.13460","volume":"18","author":"L Quartuccio","year":"2018","unstructured":"Quartuccio L, Gregoraci G, Isola M, De Vita S (2018) Retrospective analysis of the usefulness of a protocol with high-dose methotrexate in polymyalgia rheumatica: results of a single-center cohort of 100 patients. Geriatr Gerontol Int 18(9):1410\u20131414","journal-title":"Geriatr Gerontol Int"},{"issue":"4","key":"7248_CR24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1136\/ard.55.4.218","volume":"55","author":"MJ van der Veen","year":"1996","unstructured":"van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW (1996) Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 55(4):218\u2013223","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"7248_CR25","first-page":"1550","volume":"23","author":"HL Feinberg","year":"1996","unstructured":"Feinberg HL, Sherman JD, Schrepferman CG, Dietzen CJ, Feinberg GD (1996) The use of methotrexate in polymyalgia rheumatica. J Rheumatol 23(9):1550\u20131552","journal-title":"J Rheumatol"},{"issue":"5","key":"7248_CR26","doi-asserted-by":"publisher","first-page":"366","DOI":"10.5414\/CP203901","volume":"59","author":"GG Song","year":"2021","unstructured":"Song GG, Lee YH (2021) Methotrexate for treating polymyalgia rheumatica: a meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther 59(5):366\u2013371","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"7248_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7326\/M19-3369","volume":"172","author":"DH Solomon","year":"2020","unstructured":"Solomon DH, Glynn RJ, Karlson EW, Lu F, Corrigan C, Colls J et al (2020) Adverse effects of low-dose methotrexate: a randomized trial. Ann Intern Med 172(6):369\u2013380","journal-title":"Ann Intern Med"},{"issue":"11","key":"7248_CR28","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jama.2022.15459","volume":"328","author":"V Devauchelle-Pensec","year":"2022","unstructured":"Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, Richez C, Truchetet ME, Wendling D et al (2022) Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial. JAMA 328(11):1053","journal-title":"JAMA"},{"issue":"13","key":"7248_CR29","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.3390\/jcm10132948","volume":"10","author":"K Izumi","year":"2021","unstructured":"Izumi K, Murata O, Higashida-Konishi M, Kaneko Y, Oshima H, Takeuchi T (2021) Steroid-sparing effect of tocilizumab and methotrexate in patients with polymyalgia rheumatica: a retrospective cohort study. J Clin Med 10(13):2948","journal-title":"J Clin Med"},{"issue":"6","key":"7248_CR30","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","volume":"81","author":"M Bonelli","year":"2022","unstructured":"Bonelli M, Radner H, Kerschbaumer A, Mrak D, Durechova M, Stieger J et al (2022) Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial. Ann Rheum Dis 81(6):838\u2013844","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"7248_CR31","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1093\/rheumatology\/kead426","volume":"63","author":"M Assaraf","year":"2024","unstructured":"Assaraf M, Chevet B, Wendling D, Philippe P, Cailliau E, Roux C et al (2024) Efficacy and management of tocilizumab in polymyalgia rheumatica: results of a multicentre retrospective observational study. Rheumatol Oxf Engl 63(8):2065\u20132073","journal-title":"Rheumatol Oxf Engl"},{"key":"7248_CR32","unstructured":"Preuss CV, Anjum F (2024) Tocilizumab. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK570644\/. Accessed 2 Oct 2024"},{"issue":"14","key":"7248_CR33","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","volume":"389","author":"RF Spiera","year":"2023","unstructured":"Spiera RF, Unizony S, Warrington KJ, Sloane J, Giannelou A, Nivens MC et al (2023) Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper. N Engl J Med 389(14):1263\u20131272","journal-title":"N Engl J Med"},{"issue":"2","key":"7248_CR34","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/ard.45.2.136","volume":"45","author":"M De Silva","year":"1986","unstructured":"De Silva M, Hazleman BL (1986) Azathioprine in giant cell arteritis\/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 45(2):136\u2013138","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"7248_CR35","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/jppr.1610","volume":"49","author":"JL Leung","year":"2019","unstructured":"Leung JL, Owen CE, Buchanan RRC, Liew DFL (2019) Management of polymyalgia rheumatica in older people. J Pharm Pract Res 49(5):493\u2013500","journal-title":"J Pharm Pract Res"},{"issue":"610","key":"7248_CR36","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.3399\/bjgp13X667231","volume":"63","author":"T Helliwell","year":"2013","unstructured":"Helliwell T, Hider SL, Mallen CD (2013) Polymyalgia rheumatica: diagnosis, prescribing, and monitoring in general practice. Br J Gen Pract 63(610):e361\u2013e366","journal-title":"Br J Gen Pract"},{"issue":"6","key":"7248_CR37","doi-asserted-by":"publisher","first-page":"R189","DOI":"10.1186\/ar3517","volume":"13","author":"KL Garneau","year":"2011","unstructured":"Garneau KL, Iversen MD, Tsao H, Solomon DH (2011) Primary care physicians\u2019 perspectives towards managing rheumatoid arthritis: room for improvement. Arthritis Res Ther 13(6):R189","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"7248_CR38","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00296-020-04654-w","volume":"41","author":"C M\u00f8rk","year":"2021","unstructured":"M\u00f8rk C, Dam MY, Callsen MG, Keller KK (2021) The effect of a nurse-led prednisolone tapering regimen in polymyalgia rheumatica: a retrospective cohort study. Rheumatol Int 41(3):605\u2013610","journal-title":"Rheumatol Int"},{"issue":"3","key":"7248_CR39","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3899\/jrheum.110851","volume":"39","author":"M Mazzantini","year":"2012","unstructured":"Mazzantini M, Torre C, Miccoli M, Baggiani A, Talarico R, Bombardieri S et al (2012) Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol 39(3):552\u2013557","journal-title":"J Rheumatol"},{"issue":"25","key":"7248_CR40","doi-asserted-by":"publisher","first-page":"E680","DOI":"10.1503\/cmaj.190178","volume":"191","author":"J Wu","year":"2019","unstructured":"Wu J, Keeley A, Mallen C, Morgan AW, Pujades-Rodriguez M (2019) Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England. CMAJ Can Med Assoc J J Assoc Medicale Can 191(25):E680\u2013E688","journal-title":"CMAJ Can Med Assoc J J Assoc Medicale Can"},{"key":"7248_CR41","unstructured":"Prednisone [Internet]. Available from: https:\/\/go.drugbank.com\/drugs\/DB00635.\u00a0 Accessed 3\u00a0Aug 2024"},{"issue":"8","key":"7248_CR42","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/ard.61.8.718","volume":"61","author":"F Buttgereit","year":"2002","unstructured":"Buttgereit F, Da Silva JAP, Boers M, Burmester G, Cutolo M, Jacobs J et al (2002) Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 61(8):718\u2013722","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"7248_CR43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00467-018-3929-z","volume":"34","author":"AM Schijvens","year":"2019","unstructured":"Schijvens AM, ter Heine R, de Wildt SN, Schreuder MF (2019) Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome. Pediatr Nephrol Berl Ger 34(3):389\u2013403","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"7248_CR44","first-page":"495","volume-title":"Systemic glucocorticoids in rheumatology","author":"K Saag","year":"2011","unstructured":"Saag K (2011) Systemic glucocorticoids in rheumatology, 5th edn. Mosby Elsevier, Pittsburgh, pp 495\u2013503","edition":"5"},{"issue":"4","key":"7248_CR45","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/BF01060885","volume":"9","author":"JQ Rose","year":"1981","unstructured":"Rose JQ (1981) Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm 9(4):389\u2013417","journal-title":"J Pharmacokinet Biopharm"},{"key":"7248_CR46","doi-asserted-by":"publisher","unstructured":"Chikanza IC (2006) Mechanisms of corticosteroid resistance in rheumatoid arthritis. Ann N Y Acad Sci [Internet]. [cited 2024 Jul 27]; Available from: https:\/\/doi.org\/10.1111\/j.1749-6632.2002.tb04200.x","DOI":"10.1111\/j.1749-6632.2002.tb04200.x"},{"issue":"16","key":"7248_CR47","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMra050541","volume":"353","author":"T Rhen","year":"2005","unstructured":"Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids \u2014 new mechanisms for old drugs. N Engl J Med 353(16):1711\u20131723","journal-title":"N Engl J Med"},{"issue":"10411","key":"7248_CR48","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(23)01310-7","volume":"402","author":"G Esp\u00edgol-Frigol\u00e9","year":"2023","unstructured":"Esp\u00edgol-Frigol\u00e9 G, Dejaco C, Mackie SL, Salvarani C, Matteson EL, Cid MC (2023) Polymyalgia rheumatica. Lancet Lond Engl 402(10411):1459\u20131472","journal-title":"Lancet Lond Engl"},{"issue":"12","key":"7248_CR49","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1007\/s10067-023-06794-3","volume":"42","author":"GK Harris","year":"2023","unstructured":"Harris GK, Leung JL, Buchanan RRC (2023) Exploring the patient experience in polymyalgia rheumatica. Clin Rheumatol 42(12):3421\u20133422","journal-title":"Clin Rheumatol"},{"issue":"1","key":"7248_CR50","doi-asserted-by":"publisher","first-page":"e1010","DOI":"10.1002\/imed.1010","volume":"1","author":"MH Paalman","year":"2021","unstructured":"Paalman MH (2021) My new normal: a patient\u2019s perspective on polymyalgia rheumatica. ImmunoMedicine 1(1):e1010","journal-title":"ImmunoMedicine"},{"key":"7248_CR51","unstructured":"PMRGCAuk [Internet] Online health forum. Available from: https:\/\/pmrgca.org.uk\/get-support\/online-health-forum\/. Accessed 4\u00a0Oct 2024"},{"key":"7248_CR52","unstructured":"Polymyalgia Rheumatica and GCA | Bones, joints and muscles | Forums [Internet] (2022) Available from: https:\/\/patient.info\/forums\/discuss\/browse\/polymyalgia-rheumatica-and-gca-1708. Accessed 4 Oct 2024"},{"key":"7248_CR53","unstructured":"Reducing pred dose [Internet] (2020) Available from: https:\/\/patient.info\/forums\/discuss\/reducing-pred-dose-727301. Accessed 4\u00a0Oct 2024"},{"key":"7248_CR54","unstructured":"Altering pred dosage [Internet] (2016) Available from: https:\/\/patient.info\/forums\/discuss\/altering-pred-dosage-543359. Accessed 4\u00a0Oct 2024"},{"key":"7248_CR55","unstructured":"Reduction of 1 mg preds a week? [Internet] (2016) Available from: https:\/\/patient.info\/forums\/discuss\/reduction-of-1-mg-preds-a-week--552827. Accessed 4\u00a0Oct 2024"},{"issue":"6","key":"7248_CR56","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s10067-018-04405-0","volume":"38","author":"C Morton","year":"2019","unstructured":"Morton C, Muller S, Bucknall M, Gilbert K, Mallen CD, Hider SL (2019) Examining management and research priorities in patients with polymyalgia rheumatica: a primary care questionnaire survey. Clin Rheumatol 38(6):1767\u20131772","journal-title":"Clin Rheumatol"},{"issue":"2","key":"7248_CR57","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00296-021-05036-6","volume":"42","author":"J Weddell","year":"2022","unstructured":"Weddell J, Hider SL, Mallen CD, Muller S (2022) What non-pharmacological treatments do people with polymyalgia rheumatica try: results from the PMR Cohort Study. Rheumatol Int 42(2):285\u2013290","journal-title":"Rheumatol Int"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07248-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07248-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07248-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T13:58:20Z","timestamp":1736776700000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07248-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["7248"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07248-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2024,12,6]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}